Protein degradation technology: a strategic paradigm shift in drug discovery

Authors:
Open Access
Publisher website
Google Scholar
Abstract
Targeting pathogenic proteins with small-molecule inhibitors (SMIs) has become a widely used strategy for treating malignant tumors. However, most intracellular proteins have been proven to be undruggable due to a lack of active sites, leading to a significant challenge in the design and development of SMIs. In recent years, the proteolysis-targeting chimeric technology and related emerging degradation technologies have provided additional approaches for targeting these undruggable proteins. These degradation technologies show a tendency of superiority over SMIs, including the rapid and continuous target consumption as well as the stronger pharmacological effects, being a hot topic in current research. This review mainly focuses on summarizing the development of protein degradation technologies in recent years. Their advantages, potential applications, and limitations are also discussed. We hope this review would shed light on the design, discovery, and clinical application of drugs associated with these degradation technologies.
Funding Information
  • Natural Science Foundation of Zhejiang Province (LR21H280001, LQ21B020003)
  • Program of zhejiang provincial tcm sci-tech plan (2020ZZ005)
  • National Natural Science Foundation of China (81903842)

This publication has 146 references indexed in Scilit: